As Risperdal lawsuits continue to move forward in U.S. courts, a new analysis out of Germany indicates that more children in that country are being treated with antipsychotic drugs. According to a ...
WASHINGTON (Reuters) - The U.S. Supreme Court rejected a bid by Johnson & Johnson to overturn a $70 million jury verdict against the pharmaceutical company for its failure to warn about risks ...
Johnson & Johnson (NYSE:JNJ) says it has settled most of the lawsuits in the anti-psychotic drug Risperdal cases and has recorded $800 million in expenses in connection with the agreement. The medical ...
The FDA has recently approved the antipsychotic drug Risperdal for treatment of schizophrenia in adolescents ages 13-17 and for short-term treatment of bipolar disorder in youths ages 10-17. The FDA ...
Over the last few months, Johnson & Johnson has made sweeping moves to resolve a mountain of litigation involving the safety and marketing of its opioid and talc products. Friday brought word of a ...
When 15-year-old Anya Bailey of East Grand Forks developed an eating disorder after her 12th birthday, her mother took her to a psychiatrist at the University of Minnesota who prescribed a powerful ...
The FDA has recently approved the antipsychotic drug Risperdal for treatment of schizophrenia in adolescents ages 13-17 and for short-term treatment of bipolar disorder in youths ages 10-17. The FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results